Overview

Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma

Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the Everolimus aim response in children and adolescents with refractory or relapsed osteosarcoma. The aim response is defined as complete or partial response (according to RECIST criteria) for at least 4 weeks, or stable disease for at least 12 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Sidnei Epelman
Treatments:
Everolimus
Sirolimus